What is Rapid Micro Biosystems?
Headquartered in Lowell, Massachusetts, Rapid Micro Biosystems specializes in life sciences technology designed to facilitate the safe and efficient release of healthcare products. The company's flagship Growth Direct System is engineered to meet the rigorous data integrity and operational efficiency requirements of complex pharmaceutical manufacturing environments. By providing real-time, actionable insights, the platform enables manufacturers to accelerate decision-making and ensure the consistent supply of sterile injectables and advanced therapies. The company maintains a robust global footprint, with operations spanning Switzerland, Germany, the Netherlands, and the United States.
How much funding has Rapid Micro Biosystems raised?
Rapid Micro Biosystems has raised a total of $396.7M across 10 funding rounds:
Series B
$32.6M
Private Equity
$6M
Debt
$6M
Series C
$25M
Other Financing Round
$60M
Other Financing Round
$120M
Other Financing Round
$81M
Debt
$45M
Series B (2013): $32.6M supported by TPG Biotech, Longitude Capital, Quaker Partners, Kleiner Perkins Caufield & Byers, and TVM Capital
Private Equity (2014): $6M featuring Kleiner Perkins Caufield & Byers, TVM Capital, Longitude Capital, Quaker Partners, and TPG Biotech
Debt (2015): $6M, investors not publicly disclosed
Series C (2015): $25M with participation from TPG Biotech, Longitude Capital, Kleiner Perkins Caufield & Byers, TVM Capital, Richard K. Mellon and Sons, Quaker Partners, and Hepalink
Other Financing Round (2018): $60M led by Xeraya Capital and Bain Capital
Other Financing Round (2020): $120M supported by Bain Capital, Longitude Capital, Endeavour Vision, Ally Bridge Group, Xeraya Capital, and Asahi Kasei Medical
Other Financing Round (2021): $81M featuring Quaker BioVentures, Longitude Capital, Endeavour Vision, Caas Capital Management, BlackRock, Asahi Kasei Corporation, Xeraya Capital, T. Rowe Price, Sunley House Capital Management, Adage Capital Management, D1 Capital Partners, Ally Bridge Group, and Bain Capital
Debt (2025): $45M backed by Trinity Capital
Key Investors in Rapid Micro Biosystems
Bain Capital
A leading global private investment firm that manages a diverse portfolio across private equity, growth, and credit, providing strategic operational support to drive long-term value.
Longitude Capital
A healthcare-focused venture capital firm that pairs deep sector expertise with flexible capital to help biotechnology and medical technology innovators scale their operations.
TPG Biotech
The life sciences investment arm of a global alternative asset management firm, specializing in growth equity and strategic partnerships to foster innovation across the healthcare sector.
What's next for Rapid Micro Biosystems?
The latest infusion of capital is expected to accelerate the company's strategic roadmap, focusing on the global scaling of its automation platform and the expansion of its manufacturing capabilities. As the pharmaceutical industry continues to shift toward more complex, high-value therapeutic modalities, Rapid Micro Biosystems is well-positioned to capture additional market share by further integrating its MQC solutions into the digital manufacturing ecosystem. Future growth will likely center on enhancing the analytical capabilities of the Growth Direct System and deepening its penetration into emerging biotech hubs, ensuring that the company remains at the forefront of the digital transformation in healthcare quality assurance.
See full Rapid Micro Biosystems company page
